| AstraZeneca and Amgen Collaborate to Develop and Commercialise Amgen’s Clinical Inflammation Portfolio |
Abstract
|
|
Heather Cartwright |
|
| Optimer Partners with Astellas Again to Commercialise Fidaxomicin in Japan |
Abstract
|
|
Heather Cartwright |
|
| Merck & Co. Licenses Endocyte’s Phase III Cancer Drug for a Potential US$1 B |
Abstract
|
|
Heather Cartwright |
|
| Bausch & Lomb Tops Valeant with US$500 M Bid for ISTA |
Abstract
|
|
Heather Cartwright |
|
| Valeant Further Expands in Russia with Natur Produkt Purchase |
Abstract
|
|
Heather Cartwright |
|
| Spectrum Pharmaceuticals Agrees to Acquire Allos Therapeutics After Apaziquone Setback |
Abstract
|
|
Heather Cartwright |
|
| Amgen to Acquire KAI Pharmaceuticals and Gain a Potential Successor to Sensipar® |
Abstract
|
|
Heather Cartwright |
|
| Takeda Looks to Offset Revenue Losses with Bolt-On Acquisition of URL Pharma |
Abstract
|
|
Heather Cartwright |
|
| Shire Strengthens its Regenerative Medicine Business with Pervasis Therapeutics Purchase |
Abstract
|
|
Heather Cartwright |
|
| GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare |
Abstract
|
|
Heather Cartwright |
|
| Piramal Moves Further Away from Branded Generics with Purchase of Bayer Molecular Imaging Assets |
Abstract
|
|
Heather Cartwright |
|
| AstraZeneca Looks to Replenish Late-Stage Pipeline with US$1.26 B Ardea Biosciences Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Key Lessons on Royalties Too Often Learned the Hard Way |
Abstract
|
|
Nigel Borshell |
|
